亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

医学 内科学 乳腺癌 肿瘤科 激素受体 化疗 比例危险模型 激素疗法 新辅助治疗 激素疗法 癌症
作者
Marion van Mackelenbergh,Sibylle Loibl,Michael Untch,Marc E Buyse,Charles E. Geyer,Luca Gianni,Andreas Schneeweiß,PierFranco Conte,Martine J Piccart,Herve R. Bonnefoi,Christian Jackisch,Valentina Nekljudova,Gong Tang,Pinuccia Valagussa,Colin Neate,Richard D. Gelber,Coralie Poncet,Pierre Squifflet,Everardo Delforge Saad,Dominik Heinzmann
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16): 2998-3008 被引量:109
标识
DOI:10.1200/jco.22.02241
摘要

PURPOSE: The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer (EBC), and adapting postneoadjuvant therapy improves long-term outcomes for patients with HER2-positive disease not achieving pCR. We sought to investigate prognostic factors for EFS and OS among patients with and without pCR after neoadjuvant systemic treatment consisting of chemotherapy plus anti-HER2 therapy. MATERIALS AND METHODS: We used individual data from 3,710 patients randomly assigned in 11 neoadjuvant trials for HER2-positive EBC with ≥100 patients enrolled, available data for pCR, EFS, and OS, and follow-up ≥3 years. We assessed baseline clinical tumor size (cT) and clinical nodal status (cN) as prognostic factors using stratified (by trial and treatment) Cox models separately for hormone receptor-positive versus hormone receptor-negative disease, and for patients who had pCR (pCR+; ypT0/is, ypN0) versus patients who did not achieve a pCR (pCR-). RESULTS: The median follow-up overall was 61.2 months. In pCR+ patients, cT and cN were significant independent prognostic factors for EFS, whereas only cT was a significant predictor for OS. In pCR- patients, cT, cN, and hormone receptor status were significant independent predictors for both EFS and OS. Regardless of hormone receptor status, cT, and cN, the 5-year EFS/OS rates were higher in pCR+ patients than in pCR- patients. In most subsets with regards to hormone receptor and pCR status, cT and cN were independent prognostic factors for both EFS and OS, including pCR+ patients. CONCLUSION: These results confirm that patients achieving pCR have far better survival outcomes than patients who do not. The traditional poor prognostic features, namely tumor size and nodal status, remain important even after a pCR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飞快的乘风完成签到,获得积分10
刚刚
bai123完成签到,获得积分10
6秒前
CodeCraft的应助被醉酒的帅哥采纳,获得10
7秒前
fan完成签到 ,获得积分10
9秒前
斯文紫菜完成签到 ,获得积分10
9秒前
霸气糜完成签到,获得积分10
12秒前
晒晒太阳完成签到 ,获得积分10
12秒前
甜甜亦巧完成签到,获得积分10
16秒前
Orange的应助被花痴的手套采纳,获得10
18秒前
h11的应助被Gary采纳,获得10
19秒前
田様的应助被Coral369采纳,获得10
21秒前
24秒前
29秒前
优美的谷完成签到,获得积分10
31秒前
车访枫发布了新的文献求助10
31秒前
清修完成签到,获得积分0
31秒前
绫小路完成签到 ,获得积分10
32秒前
我是老大的应助被椰子云采纳,获得10
33秒前
谢凌旋完成签到,获得积分10
33秒前
袅袅完成签到 ,获得积分10
34秒前
踏实香氛完成签到,获得积分10
34秒前
ws完成签到 ,获得积分10
35秒前
众里寻你呀完成签到 ,获得积分10
38秒前
小医发布了新的文献求助10
41秒前
369ninja的应助被踏实香氛采纳,获得10
42秒前
yuanquaner完成签到,获得积分10
42秒前
妖九笙完成签到 ,获得积分10
46秒前
47秒前
嘻嘻哈哈的应助被Anakin_采纳,获得10
48秒前
48秒前
小次郎发布了新的文献求助10
51秒前
53秒前
53秒前
53秒前
55秒前
57秒前
科研启动发布了新的文献求助20
57秒前
fantasy的应助被小次郎采纳,获得10
59秒前
1分钟前
受伤青丝完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554333
关于积分的说明 21718908
捐赠科研通 7748056
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551841
邀请新用户注册赠送积分活动 2471242